此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Randomized Fistula Study

2016年3月10日 更新者:University of Pittsburgh

Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1

The primary objective of this study is to compare two treatment strategies for establishing dialysis access in patients with unsuitable forearm veins for the standard forearm primary radio-cephalic arteriovenous fistula also known as the Brescia-Cimino fistula.

研究概览

详细说明

BACKGROUND AND SIGNIFICANCE:

Among patients with end stage renal disease (ESRD) who require hemodialysis, the maintenance of an adequate vascular access is of critical importance. As the overall population in the U.S. ages, every year a greater number of patients are being maintained on hemodialysis with an estimated Medicare expenditure in excess of 1.25 billion dollars per year.1 The complications related to dialysis access are a major determinant of patient outcomes, including morbidity and mortality, and between 16-25% of hospital admissions for dialysis patients in the U.S. are related to dialysis access complications with an estimated cost of 100 million dollars.2

For patients with ESRD requiring chronic hemodialysis, the autogenous Brescia-Cimino fistula is the consensus best choice for the creation of an AV access site for hemodialysis. This type of primary fistula uses the radial artery at the wrist and a suitable cephalic vein at the level of the wrist. The fistula typically matures in 6-8 weeks when the vein and artery are normal, and provides good flow rates with a minimal incidence of ischemia of the hand. Infection rates are extremely low and long term patency is excellent. The disadvantage is a low maturation rate when the vein has segments of fibrosis from previous IV sites or venipunctures which are common in the cephalic vein at the wrist. Difficulty with fistula maturation can lead to prolonged time with a tunneled dialysis catheter (TDC) while the patient undergoes a variety of procedures to correct the fistula and allow it to mature. Up to 40% of forearm primary Brescia-Cimino fistulas either fail to mature or occlude prior to use, and the incidence of failure of forearm fistulas is significantly higher in women compared to men. Infection rates with tunneled dialysis catheters are roughly 10 times that of fistulas or grafts; therefore, months or even years with TDCs, while fistulas mature, can have consequences. Infections are estimated to account for 14% of deaths in ESRD patients.3

In the absence of a suitable cephalic vein at the wrist or in case of poor maturation, the two main options exist. They are both acceptable in clinical practice and are chosen based on the particular clinical scenario and, to some extent, surgeon preference. The options include:

  1. ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
  2. Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis. Some of these procedures, however, may involve an extensive dissection, a longer time for maturation, and the resulting fistula can be more difficult to use even if functioning well. Several procedures are also performed on occasion to aid in maturation before an AV fistula is actually available for access. In addition, a "steal" phenomenon is more common with proximal fistulas as the flow rates can be excessively high with low central resistance in the larger veins, leading to a decrease in blood flow to the hand. All of these factors often translate into prolonged central venous catheter placement (TDC) for dialysis, which has been associated with a high incidence of infection and central vein stenosis, or thrombosis.6

Because of the superior patency of primary fistulas, the Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Fistula First initiative have articulated the advantages of fistulas vs. ePTFE bridge grafts for long-term dialysis access and recommended that at least 50% of patients in any region be on dialysis through a primary fistula.7 In addition, in 2006 K/DOQI set a target of 66% for prevalent fistulas by 2009.8 Many surgeons have also adopted a 100% autogenous policy because of these recommendations without a critical assessment of the potential downside of that policy.9 Others continue to use ePTFE preferentially when a cephalic vein is not available.

Although there is no doubt that in suitable patients a primary fistula is better than a prosthetic graft, there are no data to guide the best treatment strategy in the absence of a suitable forearm cephalic vein. Although K/DOQI encourages creation of primary fistulas, the multiple procedures required for fistula maturation and prolonged time with tunneled dialysis catheters, their complications may outweigh the complications of ePTFE grafts.10

研究类型

介入性

注册 (实际的)

6

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

To participate in this study, the subject MUST have all of the following for inclusion in the study:

  • The subject must be > 18 years of age, male or female
  • Subject requires creation of dialysis access secondary to ESRD in the opinion of the referring nephrologist
  • Target arm may have a failed radiocephalic fistula
  • Contralateral failed or failing access may exist
  • The subject must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.

Exclusion Criteria:

To participate in this study, the subject may NOT HAVE any of the following at enrollment to the study:

  • Target arm has existing forearm AV graft, either functional or non-functional
  • Target arm has existing fistula, either functional or non-functional, other than a radio-cephalic at the wrist
  • Target arm has documented subclavian vein occlusion
  • Target arm has obviously suitable cephalic vein and radial artery for a primary radiocephalic fistula
  • Target arm has no superficial veins existing as options for primary access. If so, a second surgeon will review the ultrasound to confirm
  • Active local or systemic infection at the time of surgery
  • Known hypercoagulable state (e.g., antithrombin III deficiency, antiphospholipid or anticardiolipin antibodies, Factor IV Leiden, circulating lupus anticoagulant, history of heparin-induced thrombocytopenia, Protein C or S deficiency, prothrombin mutation or a history of recurrent deep venous thrombosis and/or pulmonary embolism)
  • Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.
  • Previous randomization in this trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:1 Alternative Fistula
Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
有源比较器:2 Forearm AV Graft
a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5

研究衡量的是什么?

主要结果指标

结果测量
大体时间
The primary endpoint will be the rate of composite adverse events at one year with follow-up to 3 years. Data will be tabulated every 6 months.
大体时间:12 months
12 months

次要结果测量

结果测量
大体时间
Secondary endpoints: Primary, assisted primary, and secondary patency at 1 and 3 years
大体时间:3 years
3 years
Death due to access-related illness
大体时间:3 years
3 years
Death due to any cause
大体时间:3 Years
3 Years
New central venous stenosis or occlusion
大体时间:3 years
3 years
Steal syndrome
大体时间:3 years
3 years
Neuropathy
大体时间:3 years
3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Navyash Gupta, MD、University of Pittsburgh Physicians

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年12月1日

初级完成 (实际的)

2011年1月1日

研究完成 (实际的)

2013年1月1日

研究注册日期

首次提交

2008年12月12日

首先提交符合 QC 标准的

2008年12月15日

首次发布 (估计)

2008年12月16日

研究记录更新

最后更新发布 (估计)

2016年3月11日

上次提交的符合 QC 标准的更新

2016年3月10日

最后验证

2016年3月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • Protocol #3, V1, Fistula

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Group 1: Alternative Fistula的临床试验

3
订阅